Gender-Affirming Child Abuse Prevention Act
HB4953, titled the “Gender-Affirming Child Abuse Prevention Act,” would create a federal civil cause of action for individuals who received specified gender-related medical treatment while they were minors. The bill allows the affected individual, or in some cases a guardian, family member, or estate representative, to sue the person who performed the treatment in federal district court. It authorizes recovery of actual damages or liquidated damages of $250,000 per instance, plus attorney’s fees and litigation costs.
The bill defines “gender-related medical treatment” broadly to include a range of surgeries, hormone treatments, and puberty blockers when used to address a person’s perception that their sex is not male or female. It also defines “sex,” “gender,” “female,” “male,” and “minor” in biologically fixed terms, and excludes treatment for certain disorders of sex development, ambiguous biological sex characteristics, or injuries and diseases caused or worsened by such treatment. The bill relies on interstate-commerce findings to support federal jurisdiction and would apply where the conduct involved interstate travel, communications, payments, instruments, or otherwise affected interstate commerce.
If enacted, the bill would add a new federal private right of action against medical providers and others who performed covered gender-related treatments on minors. It would expose defendants to substantial statutory damages and fee shifting, potentially increasing litigation risk for physicians, clinics, hospitals, and others involved in providing gender-affirming care to minors. The bill would not directly amend existing state medical licensing or malpractice statutes, but it would create a parallel federal remedy that could affect how such care is provided and challenged nationwide.
No committee transcripts or recorded votes were provided, so there is no formal legislative record of support or opposition in the materials supplied. Based on the bill text and title, the measure is framed as protective of minors and critical of gender-affirming care, suggesting strong support from opponents of pediatric gender transition treatment and likely strong opposition from supporters of gender-affirming care and medical providers. The absence of voting history means sentiment must be inferred from the bill’s purpose and language rather than from legislative debate.
The central point of contention is whether gender-affirming medical treatment for minors should be treated as harmful conduct giving rise to civil liability, or as legitimate medical care. Supporters of the bill are likely to argue that minors should not receive irreversible or life-altering interventions and that families need a legal remedy; opponents are likely to argue that the bill targets medically accepted care, intrudes on physician judgment, and could deter treatment for transgender youth. Additional controversy may arise from the bill’s broad definitions, its exclusion of gender identity concepts, and its use of federal commerce power to regulate conduct that is often governed by state medical law.